Journal
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
Volume 28, Issue 12, Pages 1892-1897Publisher
SAGE PUBLICATIONS INC
DOI: 10.1038/jcbfm.2008.78
Keywords
glutamate; GABA; glutamine; TCA cycle; riluzole; nuclear magnetic resonance spectroscopy
Categories
Funding
- NIDDK NIH HHS [R01 DK027121] Funding Source: Medline
- NIMH NIH HHS [K02 MH076222-03, R01 MH081211, K02 MH076222, 1K02 MH076222, R01 MH071676] Funding Source: Medline
- NINDS NIH HHS [1 P30 NS052519, P30 NS052519] Funding Source: Medline
Ask authors/readers for more resources
Riluzole is believed to modulate glutamatergic function by reducing glutamate release and facilitating astroglial uptake. We measured C-13 labeling in metabolites in prefrontal cortex and hippocampus during a 10 mins infusion of [1-C-13] glucose in urethane anesthetized rats treated with riluzole (21 days, 4 mg/kg per day, i.p.) or saline. Total and C-13 concentrations of metabolites were determined in extracts using H-1-[C-13] NMR spectroscopy. In prefrontal cortex (P < 0.05) and hippocampus (P < 0.05) riluzole increased C-13 labeling over saline in glutamate-C4 (to 112% and 130%), GABA-C2 (to 142% and 171%), and glutamine-C4 (to 118% and 233%) without affecting total metabolite levels (P > 0.2). Our findings indicate that contrary to expectation chronic riluzole enhanced glucose oxidative metabolism and glutamate/glutamine cycling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available